Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,836
  • Shares Outstanding, K 13,769
  • Annual Sales, $ 9,540 K
  • Annual Income, $ -151,180 K
  • 60-Month Beta 3.97
  • Price/Sales 3.71
  • Price/Cash Flow 1.31
  • Price/Book 0.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.17
  • Number of Estimates 1
  • High Estimate -1.17
  • Low Estimate -1.17
  • Prior Year -1.65
  • Growth Rate Est. (year over year) +29.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.40 +7.50%
on 06/13/19
3.24 -20.37%
on 05/30/19
-0.60 (-18.87%)
since 05/24/19
3-Month
2.40 +7.50%
on 06/13/19
5.47 -52.83%
on 04/08/19
-2.36 (-47.77%)
since 03/22/19
52-Week
2.40 +7.50%
on 06/13/19
11.63 -77.81%
on 02/04/19
-5.22 (-66.92%)
since 06/22/18

Most Recent Stories

More News
Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the appointment of Diane C. Young, M.D., as Senior Vice President, Chief Medical Officer, effective July 8, 2019. Over the span of a 30 year career,...

CLDX : 2.58 (+1.98%)
Why Is Celldex (CLDX) Down 29.2% Since Last Earnings Report?

Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CLDX : 2.58 (+1.98%)
Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down

Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.

ANIK : 38.74 (-3.61%)
CLDX : 2.58 (+1.98%)
LLY : 115.66 (+0.15%)
ACOR : 7.40 (-1.20%)
Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 0.88% and 13.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CLDX : 2.58 (+1.98%)
Celldex: 1Q Earnings Snapshot

HAMPTON, N.J. (AP) _ Celldex Therapeutics Inc. (CLDX) on Tuesday reported a loss of $17.2 million in its first quarter.

CLDX : 2.58 (+1.98%)
Celldex Provides Corporate Update and Reports First Quarter 2019 Results

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019.

CLDX : 2.58 (+1.98%)
Health Tech Aim to Change the Way Cancer is Treated

In 2018, there was an estimated 1.73 million new cancer cases diagnosed and 609,640 cancer deaths in the U.S., according to the American Cancer Society. The organization expects cancer cases to continue...

AVEO : 0.74 (-2.63%)
CLDX : 2.58 (+1.98%)
SRRA : 0.62 (-3.13%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
DARE : 0.81 (-2.41%)
Downtrend Call Working As Celldex Therapeu Stock Falls 21.4% (CLDX)

SmarTrend identified a Downtrend for Celldex Therapeu (NASDAQ:CLDX) on February 8th, 2019 at $6.38. In approximately 2 months, Celldex Therapeu has returned 21.41% as of today's recent price of $5.01....

CLDX : 2.58 (+1.98%)
Celldex (CLDX) Down 5.7% Since Last Earnings Report: Can It Rebound?

Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CLDX : 2.58 (+1.98%)
SmarTrend Watching for Potential Rebound in Shares of Celldex Therapeu After 9.43% Loss

Celldex Therapeu (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $4.54 to a high of $4.73. Yesterday, the shares fell 9.4%, which took the trading range below the 3-day low of $4.82...

CLDX : 2.58 (+1.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CLDX with:

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

2nd Resistance Point 2.70
1st Resistance Point 2.61
Last Price 2.58
1st Support Level 2.47
2nd Support Level 2.42

See More

52-Week High 11.63
Fibonacci 61.8% 8.10
Fibonacci 50% 7.01
Fibonacci 38.2% 5.92
Last Price 2.58
52-Week Low 2.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar